Ascendis Pharma A/S (ASND) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

23/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 5

latest quarter score

Earnings Reports

23
Ascendis Pharma (ASND) Q2 2026: €315 Million Product Revenue Fuels Biopharma Growth Trajectory
August 17, 2026
22
Ascendis Pharma (ASND) Q4 2025: Yorvipath Drives 39% Revenue Growth as Global Launch Scales
June 15, 2026
18
Ascendis Pharma (ASND) Q4 2025: Yorvipath Uptake Lifts 187M Euro, Sets Stage for 10-Country Expansion
June 15, 2026
22
Ascendis Pharma (ASND) Q1 2026: Operating Margin Hits 22% as Diversified Endocrine Portfolio Scales
May 08, 2026
21
Ascendis Pharma (ASND) Q3 2025: Yorvipath Patient Base Expands to 4,250 as Global Launch Drives Operating Profit
November 13, 2025
20
Ascendis Pharma (ASND) Q2 2025: YorbaPath Revenue Doubles, Accelerating Blockbuster Trajectory
August 08, 2025
15
Ascendis Pharma (ASND) Q1 2025: Yorvipath Drives 230% Revenue Surge, Anchoring Rare Disease Leadership
July 04, 2025
Ascendis Pharma (ASND) Q3 2024: Skytrofa Volume Up 60% as YorvaPath U.S. Launch Nears
November 14, 2024
Ascendis Pharma (ASND) Q2 2024: Skytrofa Net Revenue Down 27% as Market Access Reset Reshapes Growth Path
September 03, 2024
Ascendis Pharma (ASND) Q1 2024: Skytrofa Revenue Doubles, Lifts Path to Cash Flow Breakeven
May 02, 2024
Ascendis Pharma (ASND) Q4 2023: Skytrofa Revenue Jumps 37% QoQ as Streamlining Unlocks Breakeven Path
February 07, 2024
17
Ascendis Pharma (ASND) Q3 2023: Skytrofa Revenue Climbs 31%, Pipeline Expansion Sets Stage for 2024 Launches
November 07, 2023
Ascendis Pharma (ASND) Q2 2023: Skytrofa U.S. Revenues Raised 10M EUR on Market Share Expansion
September 05, 2023
Ascendis Pharma (ASND) Q1 2023: Skytrofa Guidance Raised 53% as Daily Growth Hormone Market Consolidates
April 27, 2023
Ascendis Pharma (ASND) Q4 2022: Skytrofa Revenue Up 17% as Daily Growth Hormone Market Consolidates
February 16, 2023

Browse all companies